Ondansetrón Bluefish (Ondansetron)

Ondansetron is employed across several clinical pathways that involve emesis control.

• Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of nausea and vomiting associated with cancer chemotherapy.
• Radiation‑induced nausea and vomiting (RINV): Helps control nausea and vomiting that occur during or after radiation treatment.
• Post‑operative nausea and vomiting (PONV): Prevents nausea and vomiting following surgical procedures.
• Hyperemesis gravidarum (severe pregnancy‑related nausea): Provides symptom relief when other treatments are insufficient.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents the initiation of the vomiting reflex triggered by chemotherapeutic agents, radiation, or surgical stress.

Side effects are generally mild but can vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported by many patients.
• Constipation: reduced bowel movements or hard stools.
• Diarrhoea: occasional loose stools.
• Fatigue: feeling unusually tired.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic drugs.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Vision changes: blurred vision or visual disturbances.

When using Ondansetrón Bluefish, consider the following safety measures:

• Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be monitored.
• Drug interactions: review concomitant medications for serotonergic activity.
• Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare professional.
• Breastfeeding: assess risk versus benefit before use.
• Renal/hepatic impairment: dose adjustment may be required; follow prescriber guidance.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Apomorphine: may cause severe hypotension and loss of consciousness.
• Certain anti‑arrhythmic drugs (e.g., quinidine, amiodarone): increase risk of QT prolongation.
• Serotonergic agents (e.g., SSRIs, MAO inhibitors): elevate risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure.
• Oral contraceptives: potential reduction in contraceptive effectiveness.